LIGNOCAINE

This brand name is authorized in Nigeria.

Active ingredients

The drug LIGNOCAINE contains one active pharmaceutical ingredient (API):

1	Lidocaine UNII V13007Z41A - LIDOCAINE HYDROCHLORIDE
	Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane.
	Read more about Lidocaine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-100994	Gel	Lignocaine Gel GEL 2% 1 x 30 g (in syringe)	Topical Gel Clear colorless gel	28/08/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D04AB01	Lidocaine	D Dermatologicals → D04 Antipruritics, incl. antihistamines, anesthetics, etc. → D04A Antipruritics, incl. antihistamines, anesthetics, etc. → D04AB Anesthetics for topical use
Discover more medicines within D04AB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-100994